$10.98
-2.0%Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
CLYM • NASDAQ
| Climb Bio, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||
-59.9M | -73.9M | -35.1M | -45.2M | -47.5M | -20.7M | -6.5M | |
97K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 5.6M | 12.8M | 7M | 3.7M | 707K | 0.0 | |
6M | 51.1M | -2.1M | 674K | 11.8M | 8.8M | 1.8M | |
-601K | 1.7M | 3.8M | 210K | -4.2M | -2.9M | -309K | |
-54.4M | -15.6M | -20.6M | -37.4M | -36.1M | -14.1M | -5M | |
INVESTING ACTIVITIES | |||||||
-186K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-108.1M | -132.2M | -58.4M | -88M | -115M | (0.0) | (0.0) | |
111.1M | 20.8M | 127.4M | 122.4M | 0.0 | 0.0 | 0.0 | |
0.0 | -9.6M | 0.0 | 0.0 | 0.0 | 8.1M | 0.0 | |
(2.8M) | -121.1M | (69M) | (34.4M) | -115M | (8.1M) | (0.0) | |
FINANCING ACTIVITIES | |||||||
-21K | 119.8M | 841K | 0.0 | 83.1M | 0.0 | 0.0 | |
0.0 | 11M | 0.0 | 0.0 | 149K | 0.0 | 0.0 | |
-21K | 130.7M | 841K | 0.0 | 177.2M | 4.9M | 26.2M | |
CASH FLOW SUMMARY | |||||||
0.0 | 42K | 304K | -408K | 245K | 359K | -12K | |
-51.5M | -5.9M | 49.5M | -3.3M | 26.4M | -736K | 21.2M | |
87.2M | 93.1M | 43.6M | 46.9M | 20.5M | 21.2M | 0.0 | |
35.7M | 87.2M | 93.1M | 43.6M | 46.9M | 20.5M | 21.2M | |
-54.5M | -15.6M | -20.6M | -37.4M | -36.1M | -14.1M | -5M |
CLYM - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
S-3 S-3 N/A | May 29, 2026 | May 29, 2026 | ||
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 05, 2026 | May 05, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 28, 2026 | April 27, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | June 05, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 03, 2026 | April 01, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 05, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 05, 2026 | March 05, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 08, 2026 | January 08, 2026 | 2026 |
Continue your CLYM research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.